ATXS — Astria Therapeutics Share News
0.000.00%
Last trade - 00:00- $718.13m
- $585.73m
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 07:59 PM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Astria Stockholders Vote To Approve Acquisition By Biocryst
Brief: Astria Therapeutics Inc - Complaints Filed Against Astria In New York Supreme Court - SEC Filing
U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, Walmart
U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, Walmart
Astria surges on BioCryst's $700 mln buyout deal
Deals of the day-Mergers and acquisitions
Astria surges on BioCryst's $700 mln buyout deal
BioCryst to buy Astria Therapeutics in $700 million deal (updated)
BioCryst to buy Astria Therapeutics in $700 million deal
Brief: BioCryst To Acquire Astria Therapeutics, Strengthening Presence In Hae, Transforming Growth Profile
Brief: Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema
Brief: Astria Reports Positive Phase 1A STAR-0310 Trial Results At European Dermatology & Venereology Congress
Brief: Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Astria Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Astria Therapeutics Inc expected to post a loss of 59 cents a share - Earnings Preview